Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study of Lucitanib (AL3810) in Patients With Advanced Recurrent or Metastatic Thymic Carcinoma Who Have Failed at Least First-line Chemotherapy

NCT07824505 is registered in ClinicalTrials.gov with Haihe Biopharma Co., Ltd. as lead sponsor.

NCT NCT07824505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07824505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study of Lucitanib (AL3810) in Patients With Advanced Recurrent or Metastatic Thymic Carcinoma Who Have Failed at Least First-line Chemotherapy
Lead sponsor
Haihe Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2018
Completion date
September 6, 2021
Enrollment
74 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced thymic carcinoma